GOP Rep. Blasts FDA Over CBD Inaction During Historic Hearing: The Agency Wants More Money To Do Its Job - Jazz Pharmaceuticals (NASDAQ:JAZZ)

For the first time, Congress officially addressed the impact of the U.S. Food and Drug Administration’s (FDA) inaction regarding the regulations of CBD products.

Related Keywords

United States ,Kentucky ,Colorado ,American ,Americans ,Jeff Merkley ,Ron Wyden ,Earl Blumenauer ,Katie Porter ,Lisa Mcclain ,Jonathan Miller ,Rand Paul ,Jazz Pharmaceuticals Jazzepidiolex ,Drug Administration ,Accountability Committee Subcommittee On Health Care ,Coalition For Access ,Financial Services ,Dvs Congress ,Modern World ,House Oversight ,Accountability Committee ,Health Care ,Republican Senator ,Hemp Access ,Consumer Safety ,Federal Food ,Cosmetics Act ,Jazz Pharmaceuticals ,Consumer Safety Act ,General Assembly ,Access Now ,Charlotte Figi ,